Vasoten

Bisoprolol fumarate

Management of HTN & angina pectoris.

HTN/angina pectoris Initially 5 mg once daily, may be increased to 10 mg once daily. Max: 20 mg once daily. Stable chronic heart failure 1.25 mg once daily for 1 wk, if well tolerated increase dose to 2.5 mg once daily for a further wk, then increase to 3.75 mg once daily for a further wk, then increase to 5 mg once daily for the following 4 wk, then increase to 7.5 mg once daily for the following 4 wk, then increase to 10 mg once daily for maintenance treatment. Max: 10 mg once daily. Severe hepatic & renal (CrCl <20 mL.min) impairment Not to exceed 10 mg daily.

May be taken with or without food: Swallow w/ some liqd, do not chew.

Hypersensitivity. Untreated cardiac failure, cardiogenic shock, SA block, 2nd/3rd degree AV block, marked bradycardia, severe asthma, sick sinus syndrome, hypotension, severe peripheral circulatory disturbances, untreated tumours of the adrenal gland (phaeochromocytoma), metabolic acidosis.

Allergic reactions. Discontinue use if precipitous pulse rate &/or BP drop occurs. DM w/ extremely fluctuating blood glucose levels, strict fasting, ongoing desensitisation therapy, 1st degree AV block, Prinzmetal's angina, peripheral arterial occlusive disease, history of psoriasis, asthma or chronic obstructive airway disease; phaeochromocytoma; thyrotoxicosis; metabolic acidosis. Patients w/ prolonged PR conduction interval, poor cardiac reserve & Raynaud's syndrome; undergoing general anaesth. Avoid anaesth agents causing myocardial depression eg, cyclopropane or trichloroethylene. Avoid abrupt discontinuation. Severe renal & hepatic impairment. Pregnancy. Not recommended during lactation.

Bradycardia. Worsened heart failure; dizziness, headache; GI complaints eg, nausea, vomiting, diarrhoea, constipation; feeling of coldness or numbness in extremities, hypotension; asthenia, fatigue.

Increased depressant effect w/ class I (eg, quinidine, disopyramide, lidocaine, phenytoin, flecainide, propafenone) & class III (eg, amiodarone) antiarrhythmics. Reduced heart muscle contractility & delayed AV impulse conduction w/ verapamil- & diltiazem-type Ca antagonists. Reduced heart rate & cardiac output w/ centrally-acting antihypertensives eg, clonidine, methyldopa, moxonodine, rilmenidine. Increased risk of hypotension w/ dihydropyridine-type Ca antagonist eg, nifedipine. Additional systemic effect w/ topical β-blockers. Increased inhibitory effect on AV impulse conduction & risk of bradycardia w/ parasympathomimetics. Intensified blood sugar-lowering effect w/ insulin & oral antidiabetic drugs. Increased risk of cardiodepressive actions leading to hypotension w/ anaesth agents. Increased impulse conduction time & reduced heart rate w/ digitalis. Reduced BP-lowering effect by NSAIDs. Reduced effects w/ β-sympathomimetic agents eg, isoprenaline, dobutamine. Increased BP & exacerbated intermittent claudication w/ β- & α-adrenoceptors eg, noradrenaline, adrenaline. Increased BP-lowering effect w/ other antihypertensives, TCAs, barbiturates, phenothiazines. Increased risk of bradycardia w/ mefloquine. Enhanced hypotensive effect w/ MAOIs.

Beta-Blockers

C07AB07 - bisoprolol ; Belongs to the class of selective beta-blocking agents. Used in the treatment of cardiovascular diseases.

B